MUC1 and cancer: However, lack of response to the vaccine was observed in patients without cancer but with a history of premalignant lesions such as advanced colon adenomas and was further characterized by an elevated concentration of MDSCs in the blood of non-responding patients (47), suggesting a rationale for simultaneous PDE5 inhibition (to lower MDSCs) and anti-MUC1 vaccination.